Combination therapy with afatinib and bevacizumab in an EGFR-mutated non-small cell lung cancer patient with acquired ERBB2 amplification
Sign Up to like & getrecommendations! Published in 2021 at "Medicine"
DOI: 10.1097/md.0000000000024380
Abstract: Abstract Introduction: Acquired resistance to reversible EGFR tyrosine kinase inhibitors remains a significant obstacle, and acquired ERBB2 amplification is the most common “bypass” mechanism. For patients with sensitizing EGFR mutation who experience resistance via ERBB2… read more here.
Keywords: combination therapy; lung; therapy afatinib; amplification ... See more keywords